In short
Sabatolimab clinical trials are studying continued treatment in adults with certain blood cancers, including higher-risk myelodysplastic syndromes and acute myeloid leukemia. These trials mainly look at safety and whether patients may continue to benefit from treatment after a prior study.
Key points
- Sabatolimab is being studied in a Phase 2 roll-over trial for adults with certain blood cancers, including higher-risk myelodysplastic syndromes, CMML-2, and acute myeloid leukemia. The trial includes people who finished a previous Sabatolimab study and may still benefit from treatment. The main focus is safety, especially the number and seriousness of adverse events and serious adverse events. The study is authorised and plans to enroll 45 participants. It is designed to see whether continued treatment can be given safely in these patient groups.
Trial overview
The source data describe one interventional study, which means the research team gives a treatment and follows what happens next. This study is a roll-over study for people who already finished a prior Novartis-sponsored Sabatolimab study and are judged by the investigator to still benefit from treatment.
The study is authorised and has the trial ID NCT05201066. It is planned for 45 participants.
Who is being studied
The trial targets adults with intermediate, high, or very high risk myelodysplastic syndromes (MDS), adults with chronic myelomonocytic leukemia - 2 (CMML-2), and adults with acute myeloid leukemia (AML) who are unfit for chemotherapy.
In simple terms, this means the study focuses on adults with serious blood diseases, including people whose disease risk is higher and people who cannot safely receive standard chemotherapy. The trial also includes patients who completed a previous Sabatolimab study and may continue to benefit from treatment.
Study design and phase
This is a Phase 2 study. Phase 2 trials usually look at safety and early signs of benefit in a specific patient group, and this source data mainly highlight safety.
The interventions listed in the source include Sabatolimab, also named MBG453, and other treatments such as venetoclax and azacitidine. The trial title and summary make clear that the main purpose is continued treatment with Sabatolimab after a prior study.
What the trial measures
The primary outcome is the frequency and severity of adverse events (AEs) and serious adverse events (SAEs). In patient-friendly language, the study checks how often unwanted medical problems happen and how serious they are.
The brief summary says the study aims to evaluate safety, including SAE and AE. No other endpoints are listed in the source data provided.
Trial summary
Overall, the available trial data describe one authorised Phase 2 roll-over study of Sabatolimab in adults with higher-risk blood cancers. The trial is focused on continued treatment after a previous study and is centered on safety monitoring. The main question is whether patients who may still benefit can keep receiving study treatment safely.